VJOncology is committed to improving our service to you

ESMO 2017 | Where to go next with pembrolizumab and other anti-PD-1 therapies in head and neck cancer

VJOncology is committed to improving our service to you

Ezra Cohen

Dr Ezra Cohen, MD, FRCPC, FASCO, from the University of California, San Diego, CA, gives his opinion on where to go next with anti-PD-1 therapy in head and neck cancer, with a focus on pembrolizumab. He is hopeful for the early data in combination studies that look quite promising. He remains confident that pembrolizumab still offers an advantage over standard of care, and should remain a part of treatment the regimen in all patients with recurrent or metastatic disease, who have failed platinum therapy. Video recorded at the ESMO 2017 Conference in Madrid, Spain.

Share this video  
Similar topics

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter